G

    Gain Therapeutics Inc (GANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.80
    +0.03 (+1.69%)

    Market Cap: $77.25M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    -13.30%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.13 - $-0.12
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.15-15.8%
    60d ago$-0.15-15.8%
    30d ago$-0.15-18.4%
    7d ago$-0.15-18.4%
    Current$-0.13
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.11 - $-0.07
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.13---
    Jun 26
    		$-0.11$-0.14+21.43%Beat+42.1%
    Mar 26
    		$-0.13$-0.14+7.14%Beat+18.8%
    Dec 25
    		$-0.11$-0.14+23.77%Beat-37.5%
    Sep 25
    		$-0.15$-0.15+0.00%Beat+11.8%
    Jun 25
    		$-0.19$-0.17-11.76%Miss+54.8%
    Mar 25
    		$-0.16$-0.17+5.88%Beat+27.3%
    Dec 24
    		$-0.08N/A+57.33%Beat+77.8%
    Sep 24
    		$-0.17$-0.21+19.05%Beat+54.1%
    Jun 24
    		$-0.42$-0.22-90.91%Miss+32.3%
    Mar 24
    		$-0.22$-0.33+33.33%Beat+48.8%
    Dec 23
    		$-0.36$-0.32-12.50%Miss+7.7%
    Sep 23
    		$-0.37$-0.46+19.57%Beat+2.6%
    Jun 23
    		$-0.62$-0.38-63.16%Miss-44.2%
    Mar 23
    		$-0.43$-0.39-10.26%Miss-53.6%
    Dec 22
    		$-0.39$-0.36-8.33%Miss-50.0%
    Sep 22
    		$-0.38$-0.46+17.39%Beat+2.6%
    Jun 22
    		$-0.43$-0.31-38.71%Miss-43.3%
    Mar 22
    		$-0.28$-0.37+24.32%Beat+44.0%
    Dec 21
    		$-0.26$-0.49+46.94%Beat-
    Sep 21
    		$-0.39$-0.33-18.18%Miss+5.0%
    Jun 21
    		$-0.30$-0.23-30.43%Miss+4.9%
    Mar 21
    		$-0.50$-0.13-284.62%Miss-
    Dec 20
    		$0.00$0.00N/ABeat-
    Sep 20
    		$-0.41$0.00N/AMiss-
    Sep 19
    		$-0.32$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.60EV/EBITDA-1.55x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-268.30%ROIC-167.72%
    Financial Health
    Debt/Equity0.03xInterest CoverageN/A
    Current Ratio4.36xQuick Ratio4.36x
    Trading Statistics
    Beta0.20Avg Volume481.68K
    52-Week High$4.3452-Week Low$1.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.92
    SMA 20$1.93
    SMA 50$1.85
    SMA 200$2.19
    EMA 10$1.88
    EMA 20$1.90
    EMA 50$1.87
    EMA 200$1.98

    MACD

    Line: 0.00Signal: 0.03Hist: -0.03

    ADX

    ADX: 16.0+DI: 18.7-DI: 23.3

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down20.0
    PSAR$2.17

    Bollinger Bands

    Upper Band$2.21
    Lower Band$1.65
    %B Position2883%(Upper)
    Band Width0.26

    RSI (14-Day)

    Neutral
    44.3

    Momentum Oscillators

    Stoch %K7.7
    Stoch %D10.9
    Williams %R-93.4
    ROC (10d)-11.8%
    Momentum-0.24
    CCI (20d)-76.0
    MFI (14d)50.3

    Volatility Measures

    ATR (14d)$0.12(6.5%)
    StdDev (20d)0.14
    Hist Vol74.4%(High)

    Volume Flow

    VWAP$1.80
    OBV13.8M
    AD Line-7.7M
    CMF (20d)-0.143

    Volume Metrics

    Avg Vol (20d)486.2K
    Vol Ratio0.5x
    VWMA (20d)$1.98

    Pivot Points

    R3$1.93
    R2$1.89
    R1$1.83
    Pivot Point$1.79
    S1$1.74
    S2$1.70
    S3$1.64

    Advanced Oscillators

    TSI0.99
    Ultimate Osc33.0
    KST84.54

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$82,242$0$0$0$64,800$0
    Cost of Revenue$0$0$-4,874,167$0$0$0$21,307$0$0$0$23,589$0
    Gross Profit$0$0$4.87M$0$0$0$-21,307$0$0$0$-23,589$0
    Operating Expenses$4.68M$5.35M$4.47M$4.79M$5.09M$4.37M$3.33M$4.46M$8.18M$4.38M$4.41M$4.89M
    R&D$2.14M$2.76M$2.35M$2.85M$2.76M$2.26M$1.22M$2.62M$4.44M$2.51M$2.37M$2.37M
    SG&A$2.54M$2.59M$2.12M$1.94M$2.33M$2.11M$2.11M$1.84M$3.75M$1.87M$2.03M$2.52M
    Operating Income$-4,681,652$-5,353,545$-4,466,023$-4,785,777$-5,089,526$-4,369,376$-3,331,104$-4,458,964$-8,182,824$-4,377,700$-4,407,230$-4,885,005
    Interest Income$61,062$93,052$83,339$78,074$42,568$40,413$51,857$105,405$84,531$115,303$0$0
    Interest Expense$0$72,121$1,442$0$578,356$60,173$0$15,734$0$0$302,237$-106,000
    Income Before Tax$-4,571,501$-5,425,666$-4,467,465$-4,735,085$-5,667,882$-4,429,549$-3,263,489$-4,474,698$-8,141,869$-3,994,320$-4,709,467$-4,696,807
    Income Tax Expense$104,070$183,066$70,116$549,288$141,205$100,509$504,738$10,994$1,209$19,874$14,502$21,456
    Net Income$-4,675,571$-5,608,732$-4,537,581$-5,284,373$-5,809,087$-4,530,058$-3,768,227$-4,485,692$-8,143,078$-4,014,194$-4,723,969$-4,718,263
    EBITDA$-4,605,393$-5,497,415$-4,522,563$-4,790,342$-5,688,122$-4,449,302$-3,294,039$-4,558,460$-8,205,807$-4,089,095$-4,792,148$-4,782,298
    EBIT$-4,632,563$-5,518,718$-4,550,804$-4,813,159$-5,710,450$-4,469,962$-3,315,346$-4,580,103$-8,226,400$-4,109,623$-4,815,737$-4,802,807
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GANX

    News

    Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

    Gain Therapeutics, a clinical-stage biotechnology company, announced that its President and CEO, Gene Mack, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held from September 14-16, 2026, in New York City, with an on-demand company presentation available starting September 11, 2026. The company is focused on discovering and developing next-generation allosteric small molecule therapies for various disorders, including Parkinson's disease.

    The Manila Times•8/25/26•
    Somewhat-Bullish

    Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8

    Roth MKM has reiterated its Buy rating for Gain Therapeutics (GANX.US) and maintained its target price of $8. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

    Moomoo•8/20/26•
    Bullish

    GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX

    GSA Capital Partners LLP has acquired a new position in Gain Therapeutics, Inc. (NASDAQ:GANX), purchasing 632,131 shares valued at approximately $1.28 million, representing a 1.48% stake in the company. Other institutional investors also adjusted their holdings, with significant increases from Marshall Wace LLP and Jane Street Group LLC. Despite a recent 3.8% decline in share price, analysts maintain a "Moderate Buy" rating for GANX with a consensus price target of $7.50, and the company reported a smaller-than-expected quarterly loss of $0.11 per share.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7

    Maxim Group has reiterated its Buy rating for Gain Therapeutics (GANX.US), maintaining a target price of $7. This indicates a continued positive outlook from the analyst firm on the company's stock performance.

    Moomoo•8/15/26•
    Bullish

    Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts

    Gain Therapeutics (NASDAQ:GANX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.50. The company recently reported a narrower-than-expected quarterly loss of $0.11 per share. Institutional investors hold a significant portion of GANX stock, with several firms initiating new positions.

    MarketBeat•8/15/26•
    Somewhat-Bullish

    Frequently Asked Questions About GANX

    Does GANX pay dividends?
    Gain Therapeutics Inc (GANX) does not currently pay a regular dividend.
    What is GANX's market cap?
    Gain Therapeutics Inc (GANX) has a market capitalization of $77.25M with a current stock price of $1.80.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In